J Gastric Cancer.
2024 Oct;24(4):353-355. 10.5230/jgc.2024.24.e40.
Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences
- Kim IH
1 - Choi W2
- Han HS3
- on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team
- Affiliations
-
- 1Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Center for Clinical Trials, National Cancer Center, Goyang, Korea
- 3Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea
- KMID: 2560577
- DOI: http://doi.org/10.5230/jgc.2024.24.e40
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences
- Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer
- Role of Adjuvant Radiotherapy in Gastric Cancer
- Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial
- A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer
